Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAE226 |
Synonyms | |
Therapy Description |
TAE226 is a dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor, (IGFIR) resulting in decreased signaling pathway activation, decreased tumor cell growth and invasion, and increased cell-cycle arrest (PMID: 17431114, PMID: 31692287). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAE226 | FAK inhibitor 15 IGF-1R Inhibitor 17 | TAE226 is a dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor, (IGFIR) resulting in decreased signaling pathway activation, decreased tumor cell growth and invasion, and increased cell-cycle arrest (PMID: 17431114, PMID: 31692287). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892). | 26090892 |
BRAF G469A | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892). | 26090892 |
BRAF G466V | lung non-small cell carcinoma | sensitive | TAE226 | Preclinical | Actionable | In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892). | 26090892 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|